Skip to content

Mechanisms of Anabolic Resistance in Older Humans

Mechanisms of Anabolic Resistance in Older Humans

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06617195
Enrollment
120
Registered
2024-09-27
Start date
2025-01-14
Completion date
2030-09-16
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Brief summary

The purpose of this research is to understand how chronic inflammation affects muscle function and responses to exercise in older adults.

Detailed description

Inflamed adipose tissue may contribute to blunted exercise response in skeletal muscle of older adults. The objective of this project is to evaluate a hypothesis that inflamed adipose secretes factors that activate inflammatory cascades in skeletal muscle, which may interfere with exercise-responsive molecular pathways and contribute to dysfunctional muscle phenotypes with aging. This project determine how adipose tissue influences skeletal muscle function and anabolic response to exercise in older adults. Young and older adults will complete studies to assess molecular response to acute exercise from protein synthesis rates, mRNA of exercise-responsive genes, and activation of signaling proteins in skeletal muscle. Adipose tissue will be assessed using a combination of non-invasive imaging and biopsy-based molecular phenotyping. The project will determine if acute exercise response is attenuated in older adults with inflamed adipose tissue phenotype.

Interventions

OTHERExercise

Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
Yes

Exclusion criteria

1. Diabetes or fasting plasma glucose 126 mg/dL 2. Body mass index (BMI) 30 kg/m2 3. Anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl) 4. Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) 5. Renal failure (serum creatinine \> 1.5mg/dl) 6. Chronic active liver disease (AST\>144IU/L or ALT\>165IU/L) 7. Oral warfarin group medications or history of blood clotting disorders. 8. Smoking 9. Pregnancy or breastfeeding 10. Alcohol consumption greater than 2 glasses/day or other substance abuse 11. Untreated or uncontrolled hypothyroidism 12. Debilitating chronic disease (at the discretion of the investigators)

Design outcomes

Primary

MeasureTime frameDescription
Anabolic response2 monthsSkeletal muscle protein synthesis rates will be measured from isotopic enrichment of muscle proteins

Countries

United States

Contacts

CONTACTRachel Passehl
passehl.rachel@mayo.edu507-255-8112
CONTACTIan Lanza
lanza.ian@mayo.edu
PRINCIPAL_INVESTIGATORIan Lanza

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026